Trial
NCT03786081
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Seagen, a wholly owned subsidiary of Pfizer
Collaborators
Genmab; European Network of Gynaecological Oncological Trial Groups (ENGOT); Belgian Gynaecological Oncology Group; GOG Foundation; Merck Sharp & Dohme LLC
Condition
Cervical Cancer
Intervention
Tisotumab Vedotin
Why stopped
Sponsor has decided to stop the trial based on strategic decisions
Provenance
Dataset: 2026-07-24 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-22